Ignite Creation Date:
2024-05-06 @ 10:04 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03152084
Status:
TERMINATED
Last Update Posted:
2021-05-28
First Post:
2017-04-18
Brief Title:
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-07-12
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-03-20
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-18
First Submit QC Date:
May 11 2017
Study First Post Date:
2017-05-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-05-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-25
Last Update Post Date:
2021-05-28
Last Update Post Date Type:
ACTUAL